EU clears €56 billion AbbVie/Allergan deal
The European Commission has approved AbbVie’s $63 billion (€56.6 billion) acquisition of Allergan, subject to the divestment of an Allergan pipeline drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.